InsiderTrades.com logo

ATXI Insider Trading

Insider Ownership Percentage: 1.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Avenue Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Avenue Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avenue Therapeutics Share Price & Price History

Current Price: $0.80
Price Change: ▲ Price Increase of +0.0395 (5.19%)
As of 12/4/2025 01:17 PM ET

This chart shows the closing price history over time for ATXI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Avenue Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/5/2024Jay D KranzlerDirectorSell61$2.24$136.64559View SEC Filing Icon  
9/8/2023Fortress Biotech, Inc.Major ShareholderBuy5,578$54.00$301,212.0013,765View SEC Filing Icon  
9/8/2023Lindsay A Md RosenwaldDirectorBuy4,649$54.00$251,046.004,724View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Avenue Therapeutics (NASDAQ:ATXI)

17.34% of Avenue Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ATXI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Avenue Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2025Boothbay Fund Management LLC41,089$82K0.0%N/A2.004%Search for SEC Filing on Google Icon
10/18/2024Moss Adams Wealth Advisors LLC11,000$27K0.0%N/A1.169%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC75,000$0.26M0.0%N/A7.970%Search for SEC Filing on Google Icon
1/28/2022National Asset Management Inc.71,338$65K0.0%-20.1%0.376%Search for SEC Filing on Google Icon
11/16/2021National Asset Management Inc.89,237$0.13M0.0%-29.2%0.531%Search for SEC Filing on Google Icon
10/19/2021Kestra Advisory Services LLC22,500$34K0.0%N/A0.134%Search for SEC Filing on Google Icon
9/3/2021Parametric Portfolio Associates LLC10,554$26K0.0%-59.2%0.063%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp13,767$35K0.0%-82.1%0.082%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Avenue Therapeutics logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Read More on Avenue Therapeutics

Today's Range

Now: $0.80
Low: $0.80
High: $0.80

50 Day Range

MA: $0.77
Low: $0.70
High: $0.93

52 Week Range

Now: $0.80
Low: $0.17
High: $2.23

Volume

2,077 shs

Average Volume

123,423 shs

Market Capitalization

$2.55 million

P/E Ratio

0.04

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Avenue Therapeutics?

Avenue Therapeutics' top insider shareholders include:
  1. Jay D Kranzler (Director)
Learn More about top insider investors at Avenue Therapeutics.